Logo image of HMHC

HOUGHTON MIFFLIN HARCOURT CO (HMHC) Stock Fundamental Analysis

NASDAQ:HMHC - Nasdaq - Common Stock

21.03  +0.02 (+0.1%)

After market: 21.12 +0.09 (+0.43%)

Fundamental Rating

2

HMHC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Diversified Consumer Services industry. HMHC may be in some trouble as it scores bad on both profitability and health. HMHC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HMHC was profitable.
HMHC Yearly Net Income VS EBIT VS OCF VS FCFHMHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M -400M

1.2 Ratios

Industry RankSector Rank
ROA 10.82%
ROE 64.63%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HMHC Yearly ROA, ROE, ROICHMHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400 -500

1.3 Margins

Industry RankSector Rank
OM 5.41%
PM (TTM) 20.32%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HMHC Yearly Profit, Operating, Gross MarginsHMHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, HMHC has more shares outstanding
The debt/assets ratio for HMHC has been reduced compared to a year ago.
HMHC Yearly Shares OutstandingHMHC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
HMHC Yearly Total Debt VS Total AssetsHMHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 1B 2B 3B

2.2 Solvency

HMHC has an Altman-Z score of -1.16. This is a bad value and indicates that HMHC is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.96 indicates that HMHC is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Altman-Z -1.16
ROIC/WACCN/A
WACCN/A
HMHC Yearly LT Debt VS Equity VS FCFHMHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.39 indicates that HMHC should not have too much problems paying its short term obligations.
HMHC has a Quick Ratio of 1.18. This is a normal value and indicates that HMHC is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.18
HMHC Yearly Current Assets VS Current LiabilitesHMHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 104.02% over the past year.
The Revenue has been growing slightly by 5.80% in the past year.
HMHC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.05% yearly.
EPS 1Y (TTM)104.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)5.8%
Revenue growth 3Y-7.38%
Revenue growth 5Y-4.05%
Sales Q2Q%-12.18%

3.2 Future

The Earnings Per Share is expected to grow by 67.54% on average over the next years. This is a very strong growth
HMHC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.84% yearly.
EPS Next Y388.14%
EPS Next 2Y201.14%
EPS Next 3Y95.59%
EPS Next 5Y67.54%
Revenue Next Year3.98%
Revenue Next 2Y3.95%
Revenue Next 3Y3.37%
Revenue Next 5Y2.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HMHC Yearly Revenue VS EstimatesHMHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B
HMHC Yearly EPS VS EstimatesHMHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

HMHC is valuated quite expensively with a Price/Earnings ratio of 300.43.
When comparing the Price/Earnings ratio of HMHC to the average of the S&P500 Index (29.62), we can say HMHC is valued expensively.
With a Price/Forward Earnings ratio of 61.55, HMHC can be considered very expensive at the moment.
HMHC is valuated expensively when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 300.43
Fwd PE 61.55
HMHC Price Earnings VS Forward Price EarningsHMHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.11
HMHC Per share dataHMHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

HMHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HMHC's earnings are expected to grow with 95.59% in the coming years.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y201.14%
EPS Next 3Y95.59%

More info and screens

0

5. Dividend

5.1 Amount

HMHC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOUGHTON MIFFLIN HARCOURT CO

NASDAQ:HMHC (4/6/2022, 8:00:02 PM)

After market: 21.12 +0.09 (+0.43%)

21.03

+0.02 (+0.1%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-24 2022-02-24/bmo
Earnings (Next)05-05 2022-05-05/bmo
Inst Owners1.13%
Inst Owner Change0%
Ins Owners0.59%
Ins Owner Change0%
Market Cap2.69B
Analysts45.71
Price Target21.42 (1.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 300.43
Fwd PE 61.55
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B 8.13
P/tB N/A
EV/EBITDA 10.11
EPS(TTM)0.07
EY0.33%
EPS(NY)0.34
Fwd EY1.62%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.23
BVpS2.59
TBVpSN/A
PEG (NY)0.77
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.82%
ROE 64.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 5.41%
PM (TTM) 20.32%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.18
Altman-Z -1.16
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y388.14%
EPS Next 2Y201.14%
EPS Next 3Y95.59%
EPS Next 5Y67.54%
Revenue 1Y (TTM)5.8%
Revenue growth 3Y-7.38%
Revenue growth 5Y-4.05%
Sales Q2Q%-12.18%
Revenue Next Year3.98%
Revenue Next 2Y3.95%
Revenue Next 3Y3.37%
Revenue Next 5Y2.84%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A